Henry Schein, Inc. (HSIC) Return on Equity (ROE): 12.09%
Is Henry Schein, Inc.’s return on equity (ROE) high or low?
Henry Schein, Inc.'s return on equity (ROE) of 12.09% is 10% below its 5-year average of 13.50%, near the low end of its 5-year range (11.38%–18.22%).
As of Tuesday, June 23, 2026. 1.77% above its 12-month average of 11.88%.
HSIC Return on Equity (ROE) Chart
HSIC Average Return on Equity (ROE) Chart
HSIC Current vs Average Return on Equity (ROE) Chart
HSIC Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
12.09%
RETURN ON EQUITY (ROE) AVG TTM
11.88%
RETURN ON EQUITY (ROE) AVG 3Y
12.69%
RETURN ON EQUITY (ROE) AVG 5Y
13.50%
RETURN ON EQUITY (ROE) AVG 10Y
15.02%
RETURN ON EQUITY (ROE) AVG 15Y
15.08%
RETURN ON EQUITY (ROE) AVG 20Y
14.58%
CURRENT VS TTM AVG
+1.77%
CURRENT VS 3Y AVG
-4.71%
CURRENT VS 5Y AVG
-10.42%
CURRENT VS 10Y AVG
-19.51%
CURRENT VS 15Y AVG
-19.80%
CURRENT VS 20Y AVG
-17.10%
HSIC Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Henry Schein, Inc. (HSIC) | $8.96B | 12.09% | 11.88% | 12.69% | 13.50% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.75B | -6.28% | -2.13% | 6.32% | 9.65% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | -72.74% | -651.33% | -315.37% | -198.08% |
| Baxter International Inc. (BAX)vs › | $10.15B | -18.17% | -12.46% | -8.76% | -1.37% |
| Oscar Health, Inc. (OSCR)vs › | $7.63B | -2.37% | -21.41% | -36.14% | -25.75% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.60B | 2.46% | -8.94% | -15.72% | 1.14% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.48B | -2.97% | 25.09% | 5.57% | 0.40% |
| Revvity, Inc. (RVTY)vs › | $11.05B | 3.35% | 3.59% | 3.35% | 7.68% |
| Align Technology, Inc. (ALGN)vs › | $12.44B | 10.36% | 10.54% | 10.84% | 19.93% |
Return Analysis
ROE
12.1%
ROA
3.5%
Henry Schein, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Henry Schein, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Henry Schein, Inc. (HSIC)?
- The return on equity (ROE) for HSIC stock is 12.09%.
- Is Henry Schein, Inc.'s return on equity (ROE) high or low?
- Henry Schein, Inc.'s return on equity (ROE) of 12.09% is 10% below its 5-year average of 13.50%, near the low end of its 5-year range (11.38%–18.22%).
- What is the TTM average return on equity (ROE) for Henry Schein, Inc. (HSIC)?
- The TTM average return on equity (ROE) for HSIC stock is 11.88%.
- What is the 3Y average return on equity (ROE) for Henry Schein, Inc. (HSIC)?
- The 3Y average return on equity (ROE) for HSIC stock is 12.69%.
- What is the 5Y average return on equity (ROE) for Henry Schein, Inc. (HSIC)?
- The 5Y average return on equity (ROE) for HSIC stock is 13.50%.
- What is the 10Y average return on equity (ROE) for Henry Schein, Inc. (HSIC)?
- The 10Y average return on equity (ROE) for HSIC stock is 15.02%.
- What is the 15Y average return on equity (ROE) for Henry Schein, Inc. (HSIC)?
- The 15Y average return on equity (ROE) for HSIC stock is 15.08%.
- What is the 20Y average return on equity (ROE) for Henry Schein, Inc. (HSIC)?
- The 20Y average return on equity (ROE) for HSIC stock is 14.58%.
Henry Schein, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-27 | 12.27% |
| 2024-12-28 | 11.49% |
| 2023-12-31 | 11.38% |
| 2022-12-31 | 15.61% |
| 2021-12-31 | 18.22% |
| 2020-12-31 | 12.01% |
| 2019-12-31 | 16.94% |
| 2018-12-31 | 18.10% |
| 2017-12-31 | 14.45% |
| 2016-12-31 | 18.14% |
| 2015-12-31 | 16.61% |
| 2014-12-31 | 16.57% |
| 2013-12-31 | 15.94% |
| 2012-12-31 | 14.85% |
| 2011-12-31 | 15.12% |
| 2010-12-31 | 13.51% |
| 2009-12-31 | 14.28% |
| 2008-12-31 | 13.96% |
| 2007-12-31 | 13.20% |
| 2006-12-31 | 12.42% |
| 2005-12-31 | 11.19% |
| 2004-12-31 | 11.59% |
| 2003-12-31 | 13.69% |
| 2002-12-31 | 13.70% |
| 2001-12-31 | 12.84% |
| 2000-12-31 | 9.80% |
| 1999-12-31 | 9.71% |
| 1998-12-31 | 3.52% |
| 1997-12-31 | -0.24% |
| 1996-12-31 | 4.83% |
Related Metrics
About Henry Schein, Inc.
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Andrea Albertini